Kazia Therapeutics Limited — FY2019 Form 20-F Summary
Period clarification: The supplied filing is an annual report for the fiscal year ended June 30, 2019, not a standalone 2018 fourth-quarter filing. Financial statements are prepared under IFRS and presented in Australian dollars (A$).
Business context
Kazia is an early-stage oncology biotechnology company with no product sales. Its principal clinical programs are GDC-0084 (later provisionally named paxalisib), a brain-penetrant PI3K/Akt/mTOR inhibitor, and Cantrixil, a potential ovarian-cancer therapy. The company’s ADSs trade on Nasdaq as KZIA; each ADS represents ten ordinary shares.
Key financial metrics
| Metric | FY2019 | FY2018 |
|---|---|---|
| Product revenue | None | None; reported revenue was A$119,000 |
| Other income | A$1.465 million | A$12.989 million |
| Net loss | A$10.270 million | A$6.039 million |
| Basic and diluted loss per share | A$0.1786 | A$0.1248 |
| Research and development expense | A$6.476 million | A$9.774 million |
| General and administrative expense | A$3.786 million | A$5.598 million |
| Net cash used in operating activities | A$6.714 million | A$8.661 million |
| Cash and cash equivalents at year end | A$5.434 million | A$5.956 million |
| Total assets / total liabilities | A$21.177 million / A$6.982 million | A$28.175 million / A$8.933 million |
| Net assets / accumulated losses | A$14.195 million / A$24.948 million | A$19.242 million / A$14.641 million |
The company reported no borrowings or credit facility. Short-term deposits included in cash totaled A$4.6 million at a weighted average interest rate of 1.88%. A$464,000 of Triaxial convertible notes is presented as equity, not debt, and may convert into shares on specified milestones. No dividends were declared.
Changes versus FY2018
- Net loss widened by A$4.231 million despite lower R&D and administrative expenses. FY2018 included an A$8.411 million gain from a legal settlement and a A$1.461 million gain on contingent consideration revaluation; those benefits did not recur.
- R&D expense fell 34% and general and administrative expense fell 33%, reflecting program prioritization, out-licensing of early-stage assets, and cost reductions.
- Operating cash outflow improved by A$1.947 million. Financing provided A$3.816 million, principally from an October 2018 placement and a shareholder purchase plan; investing cash inflow of A$2.359 million came from selling shares in another listed company.
- Cash declined A$522,000 year over year. Ordinary shares outstanding increased from 48.4 million to 62.2 million, including shares issued in the placement, purchase plan, and for an acquisition milestone.
Outlook, risks and unusual items
- Funding and going concern: Management said available cash was expected to fund R&D activities until approximately the end of calendar 2019 and anticipated further capital, grant, licensing, or partnering needs. The auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Management used the going-concern basis, while acknowledging material uncertainty if funding assumptions fail.
- Clinical outlook: FY2020 anticipated results from the Cantrixil Phase I trial, GDC-0084 glioblastoma Phase II study, and initial GDC-0084 studies in pediatric DIPG and breast-cancer brain metastases. These are forecasts, not guaranteed outcomes.
- Preliminary trial observations: GDC-0084 dose escalation reached a 60 mg maximum tolerated dose in newly diagnosed glioblastoma patients; the expansion cohort was recruiting. In Cantrixil’s initial dose-escalation cohort, five of nine evaluable patients had stable disease; the filing described these as early findings, with expansion-cohort data expected later.
- R&D rebate: The company accrued A$1.431 million for the FY2019 Australian R&D tax incentive, compared with A$2.2 million in FY2018. The rebate is subject to eligibility and government approval.
- Contingencies: A patent dispute with Austrian company APOtrend remained unresolved as to claims and potential damages. Kazia provided a court guarantee of €250,000 (A$387,657); potential damages were not limited to that amount. The related receivable remained fully impaired.
- Other risks: Clinical efficacy or safety failures, dependence on external manufacturers and trial partners, further financing and shareholder dilution, intellectual-property challenges, regulatory delays, and volatile securities prices could materially affect the business.
Important facts for investors to verify
- Current cash runway, subsequent financing, and whether the company addressed the auditor’s substantial-doubt going-concern warning.
- Actual clinical-trial enrollment, safety findings, and efficacy results versus the filing’s anticipated timelines and early observations.
- Receipt and eligibility of the accrued A$1.431 million R&D rebate and the sustainability of future grant support.
- Potential timing, settlement form, and dilution from milestone obligations and the A$464,000 convertible note.
- Status and possible financial exposure of the APOtrend dispute and court guarantee.